

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Novel Challenges and Therapeutic Options for Liver Diseases

Guest Editor:

Prof. Dr. Guido Gerken

1. Professor Emeritus,
Department of Gastroenterology
and Hepatology, University
Hospital, University of DuisburgEssen, D-45122 Essen, Germany
2. Senior Consultant, Helios
Klinikum Niederberg, 42549
Velbert, Germany

Deadline for manuscript submissions:

closed (1 February 2024)

Message from the Guest Editor

Liver diseases represent one of the greatest health problems worldwide and are one of the leading causes of death. Acute and chronic liver diseases and their consequences are the second most common medical care problem. The importance of the early detection and timely treatment of various liver diseases and their primary and secondary prevention should therefore be at the highest priority worldwide.

In the last three decades, in particular, groundbreaking developments in the diagnosis and therapy of liver diseases have been made thanks to scientific advances. In this Special Issue, research topics range from viral diseases to autoimmune, vascular, metabolic, and genetic diseases to liver cirrhosis and its subsequent complications, acute chronic liver failure, and the development of primary liver cell carcinomas are warmly welcome. Topics such as therapeutic immunization, cell-based tumor therapy, liverguts interaction based on the microbiome, and precision medicine using the example of the molecular profiling of tumors will be also covered.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
 Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us